Boehringer Ingelheim, Quallent partner to expand Humira biosimilar access

Key takeaways:

• Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm.
• The existing biosimilar interchangeability designation will continue.

Boehringer Ingelheim has partnered with Quallent Pharmaceuticals to expand access to its Humira biosimilar citrate-free adalimumab-adbm in the United States, according to a company press release.

Quallent, a private label pharmaceutical distributor, will offer both high-concentration (40 mg/0.4 mL) and low-concentration (40 mg/0.8 mL) citrate-free formulations of adalimumab-adbm as a pre-filled syringe or pen. Boehringer Ingelheim will manufacture the Quallent products, and the company will continue to commercialize Cyltezo (adalimumab-adbm) injection and adalimumab-adbm.

Boehringer Ingelheim’s existing interchangeability designation for the low-concentration formula will be offered with Quallent’s formula.

Quallent also intends to offer a copay assistance program for adalimumab-adbm, John Caulfield, president of Quallent Pharmaceuticals Health LLC, said in the release.

“Boehringer Ingelheim is dedicated to broadening access to essential biologic medicines, and our collaboration with Quallent will increase availability of our adalimumab biosimilar for patients living with certain chronic inflammatory diseases,” Chris Marsh, senior vice president of value and access at Boehringer Ingelheim, said in the release.